Is breast cancer overdiagnosed or isn’t it? The argument goes on

People taking sides in the mammography debates have a fresh controversy to feed on. This one has some Ivy League heft—and a pointed statement from the American College of Radiology—behind it.

Last week the New England Journal of Medicine published an opinion piece penned by two Dartmouth doctors and a special report by two Yale Cancer Center physicians.

Both papers advanced positions on avoiding cancer overdiagnosis.

Screening mammography “causes considerable overdiagnosis” and its “effectiveness is limited,” wrote Donald Lannin, MD, and Shiyi Wang, MD, PhD, of Yale. “Because of the long lead times, mammography is very good at detecting tumors with favorable biologic features, and therefore these tumors are overrepresented among small tumors. However, many of them do not progress within the patient’s lifetime; therefore, they contribute substantially to overdiagnosis.”

“Although it’s possible that [favorable] mortality trends can be explained by higher rates of screening resulting in fewer cancer deaths in high-income counties, such a benefit would have come at a cost—using these data, 5 to 10 overdiagnosed patients for every death averted,” wrote H. Gilbert Welch, MD, MPH, and Elliott Fisher, MD, MPH, of Dartmouth. (They looked at, but didn’t limit their case to, the place of breast cancer in general cancer overdiagnosis.)

The ACR posted a statement that read, in part:

“[M]any breast cancer opinions stated in the Welch-Fisher perspective and the Lannin-Wang special report on overdiagnosis, survival and screening vs. treatment effectiveness are refuted by direct patient data in respected studies. These two papers … are based on assumptions, many of which are unsupported, rather than direct patient data and should not affect breast cancer screening policy.”

Click here to read the full ACR response.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.